[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365349-105":59,"doc-detail-365349-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synnotch-car-t-cell-when-synthetic-biology-and-immunology-meet-again","SynNotch CAR-T cell, when synthetic biology and immunology meet again","","Cancer immunotherapy has been transformed by chimeric antigen receptor (CAR) T-cell treatment, which has produced major results in hematological malignancies, but solid tumors remain difficult due to immune evasion, tumor heterogeneity, and safety risks from off-target effects. This review addresses how synthetic Notch (synNotch) receptors change the design space by acting as versatile, receptor-ligand–modeled signaling platforms. By functioning as molecular logic gates, synNotch receptors enable precise, multi-antigen control of T-cell activation and support spatiotemporally regulated gene expression. The article summarizes synNotch receptor design principles and highlights emerging strategies to improve efficacy, safety, and adaptability for treating solid tumors, focusing on synNotch-based CAR-T cell potential to overcome limitations of traditional approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synnotch-car-t-cell-when-synthetic-biology-and-immunology-meet-again/365349/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synnotch-car-t-cell-when-synthetic-biology-and-immunology-meet-again/365349.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major limitation of CAR-T therapy affects solid tumors?","Question",{"text":112,"@type":113},"Solid tumors pose challenges including immune evasion, tumor heterogeneity, and safety concerns from off-target effects, limiting CAR-T performance compared with hematological malignancies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do synNotch receptors improve control of T-cell activation?",{"text":117,"@type":113},"synNotch receptors function as molecular logic gates modeled on natural receptor-ligand interactions, enabling precise multi-antigen regulation of T-cell activation.",{"name":119,"@type":110,"acceptedAnswer":120},"What design feature helps synNotch receptors distinguish cancerous from normal cells?",{"text":121,"@type":113},"They support spatiotemporally controlled gene expression, which allows more discriminating targeting behavior between cancerous and normal cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365349,1790194616,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 16 April 2025  \nDOI 10.3389/fimmu.2025.1545270  \nOPEN ACCESS  \nEDITED BY  \nPhilipp C. Rommel,  \nUniversity of Pennsylvania, United States  \nREVIEWED BY  \nJiaqian Qi,  \nThe First Afﬁliated Hospital of Soochow University, China  \nTalar Tokatlian,  \nA2 Biotherapeutics, Inc., United States Senthilnath Lakshmanachetty, University of California San Francisco, United States  \n*CORRESPONDENCE  \nFatemeh Rahbarizadeh  \n [rahbarif@modares.ac.ir](rahbarif@modares.ac.ir)  \nRECEIVED 14 December 2024  \nACCEPTED 28 March 2025  \nPUBLISHED 16 April 2025  \nCITATION  \nShirzadian M, Moori S, Rabbani R and Rahbarizadeh F (2025) SynNotch CAR-T cell, when synthetic biology and immunology meet again.  \nFront. Immunol. 16:1545270 .  \ndoi: 10.3389/fimmu.2025.1545270  \nCOPYRIGHT  \n© 2025 Shirzadian, Moori, Rabbani and Rahbarizadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSynNotch CAR-T cell, when synthetic biology and immunology meet again  \nMohsen Shirzadian 1, Sepideh Moori 2, Reza Rabbani 3 and Fatemeh Rahbarizadeh 2*  \n1 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran, 2 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, 3 Department of Stem Cell Technology and Tissue Engineering, Faculty of Interdisciplinary Science and Technology, Tarbiat Modares University, Tehran, Iran  \nCancer immunotherapy has been transformed by chimeric antigen receptor (CAR) T-cell treatment, which has shown groundbreaking results in hematological malignancies. However, its application in solid tumors remains a formidable challenge due to immune evasion, tumor heterogeneity, and safety concerns arising from off-target effects. A long-standing effort in this ﬁeld has been the development of synthetic receptors to create new signaling pathways and rewire immune cells for the speciﬁc targeting of cancer cells, particularly in cell-based immunotherapy. This ﬁeld has undergone a paradigm shift with the introduction of synthetic Notch (synNotch) receptors, which offer a highly versatile signaling platform modeled after natural receptor-ligand interactions. By functioning as molecular logic gates, synNotch receptors enable precise, multi-antigen regulation of T-cell activation, paving the way for enhanced speciﬁcity and control. This review explores the revolutionary integration of synNotch systems with CAR T-cell therapy, emphasizing cutting-edge strategies to overcome the inherent limitations of traditional approaches. We delve into the mechanisms of synNotch receptor design, focusing on their ability to discriminate between cancerous and normal cells through spatiotemporally controlled gene expression. Additionally, we highlight recent advancements to improve therapeutic efﬁcacy, safety, and adaptability in treating solid tumors. This study highlights the potential of synNotch-based CAR-T cells to transform the ﬁeld of targeted cancer therapy by resolving present challenges and shedding light on potential future paths.  \nKEYWORDS  \nsynNotch receptor, CAR-T cell therapy, synthetic biology, immunotherapy, cancer, molecular logic-gates  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Background  \nSynthetic biology, a ﬁeld that merges engineering principles with biology, has revolutionized the development of novel therapeutic strategies. By designing and constructing new biological systems, researchers are able to engineer cells with enhanced functions, such as the ability to target and destroy cancer cells. Synthetic rece","cbCaimWPd6yEFgT2","https://ap.wps.com/l/cbCaimWPd6yEFgT2","pdf",1289800,"English","# Background\n# Chimeric Antigen Receptor (CAR) T cells and approved therapies\n# Challenges in solid tumors\n# Promise and design principles of synNotch CAR-T systems","[{\"question\":\"What major limitation of CAR-T therapy affects solid tumors?\",\"answer\":\"Solid tumors pose challenges including immune evasion, tumor heterogeneity, and safety concerns from off-target effects, limiting CAR-T performance compared with hematological malignancies.\"},{\"question\":\"How do synNotch receptors improve control of T-cell activation?\",\"answer\":\"synNotch receptors function as molecular logic gates modeled on natural receptor-ligand interactions, enabling precise multi-antigen regulation of T-cell activation.\"},{\"question\":\"What design feature helps synNotch receptors distinguish cancerous from normal cells?\",\"answer\":\"They support spatiotemporally controlled gene expression, which allows more discriminating targeting behavior between cancerous and normal cells.\"}]","SynNotch CAR-T cell, when synthetic biology and immunology meet again | PDF",1790160700,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/364cefec24f46cc43b6e8692d9072f8f.webp",983,1389,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbb95b6f1fb96a3551da28aa21231d60.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b8c52761004a3f8e9668e5769dbefa0.webp",981,1386,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8b548ec22135dd698ccc89ae5729f3a.webp",980,1385]